CELC Celcuity Inc
Price (delayed)
$10.8
Market cap
$408.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.83
Enterprise value
$484.1M
Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia,
Highlights
The debt has soared by 162% YoY
CELC's net income has plunged by 75% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of CELC
Market
Valuations
Earnings
Shares outstanding
37.84M
Market cap
$408.67M
Enterprise value
$484.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$113.27M
Net income
-$111.78M
EBIT
-$101.5M
EBITDA
-$101.37M
Free cash flow
-$83.72M
Per share
Balance sheet
Liquidity
EPS
-$2.83
EPS diluted
-$2.83
Free cash flow per share
-$2.12
Book value per share
$3.11
Revenue per share
$0
TBVPS
$6.21
Total assets
$245.12M
Total liabilities
$129.5M
Debt
$97.95M
Equity
$115.62M
Working capital
$212.85M
Debt to equity
0.85
Current ratio
7.71
Quick ratio
7.41
Net debt/EBITDA
-0.74
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-44.8%
Return on equity
-77.7%
Return on invested capital
-35.7%
Return on capital employed
-47.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CELC stock price
How has the Celcuity stock price performed over time
Intraday
-2.17%
1 week
5.47%
1 month
2.76%
1 year
-31.52%
YTD
-17.49%
QTD
6.82%
Financial performance
How have Celcuity's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$113.27M
Net income
-$111.78M
Gross margin
N/A
Net margin
N/A
CELC's net income has plunged by 75% YoY and by 19% from the previous quarter
The operating income has dropped by 71% year-on-year and by 17% since the previous quarter
Growth
What is Celcuity's growth rate over time
Valuation
What is Celcuity stock price valuation
P/E
N/A
P/B
3.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 9% QoQ and by 5% YoY
The equity has contracted by 23% from the previous quarter and by 17% YoY
CELC's price to book (P/B) is 9% less than its last 4 quarters average of 3.9 and 7% less than its 5-year quarterly average of 3.8
Efficiency
How efficient is Celcuity business performance
The ROE has decreased by 42% YoY and by 24% from the previous quarter
The return on assets has declined by 15% year-on-year and by 13% since the previous quarter
Celcuity's return on invested capital has decreased by 8% QoQ but it has increased by 2.7% YoY
Dividends
What is CELC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CELC.
Financial health
How did Celcuity financials performed over time
Celcuity's total assets is 89% more than its total liabilities
CELC's total liabilities has surged by 152% year-on-year and by 5% since the previous quarter
Celcuity's current ratio has decreased by 43% YoY and by 26% from the previous quarter
The debt is 15% less than the equity
The debt has soared by 162% YoY
The company's debt to equity rose by 31% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.